Cardioprotective effect of histamine H2 antagonists in congestive heart failure: A systematic review and meta-analysis
- PMID: 29642208
- PMCID: PMC5908598
- DOI: 10.1097/MD.0000000000010409
Cardioprotective effect of histamine H2 antagonists in congestive heart failure: A systematic review and meta-analysis
Abstract
Background: Histamine H2 antagonists (H2RAs) have long been suggested to have beneficial effects on congestive heart failure (CHF). However, full agreement about the cardioprotective effects of H2RAs is still not reached yet. Therefore, this study aims to clarify the effects of H2RAs on myocardial function in CHF patients by meta-analysis.
Methods: Electronic databases including PubMed, Embase, and Cochrane Library were retrieved. Randomized controlled trials comparing the cardiac effects of H2RAs and placebo or other medicines were collected. Pooled mean differences (MDs) with 95% confidence intervals (CIs) were calculated and meta-analysis was performed using RevMan 5.3 software.
Results: A total of 10 studies (472 participants) were included in this meta-analysis. H2RAs exhibited significant negative inotropic and chronotropic effects to reduce heart rate (MD: -3.90; 95%CI: -7.07 to -0.73, P = .02). Furthermore, although H2RAs did not affect the blood pressure in health volunteers, they significantly decreased the blood pressure of CHF patients. Additionally, H2RAs were also associated with significant increase in pre-ejection period and the ratio of pre-ejection period to left ventricular ejection time.
Conclusion: In summary, these findings showed that H2RAs exerted negative inotropic and chronotropic effects to reduce heart rate and blood pressure, which, similar to beta-adrenergic receptor blockers, might decrease myocardial oxygen demand and eventually result in improvement of CHF symptoms. These data provided further evidence for the effect of H2RAs on cardiac function and novel potential strategy for treatment of CHF.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures










Similar articles
-
Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units.Cochrane Database Syst Rev. 2018 Jun 4;6(6):CD008687. doi: 10.1002/14651858.CD008687.pub2. Cochrane Database Syst Rev. 2018. PMID: 29862492 Free PMC article.
-
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.Cochrane Database Syst Rev. 2018 Jun 28;6(6):CD012721. doi: 10.1002/14651858.CD012721.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2021 May 22;5:CD012721. doi: 10.1002/14651858.CD012721.pub3. PMID: 29952095 Free PMC article. Updated.
-
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD014638. doi: 10.1002/14651858.CD014638.pub2. Cochrane Database Syst Rev. 2022. PMID: 36162822 Free PMC article.
-
Digitalis for treatment of congestive heart failure in patients in sinus rhythm.Cochrane Database Syst Rev. 2004;(2):CD002901. doi: 10.1002/14651858.CD002901.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2014 Apr 28;(4):CD002901. doi: 10.1002/14651858.CD002901.pub3. PMID: 15106182 Updated.
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
Cited by
-
Histamine H2 Receptor Antagonists and Heart Failure Risk in Postmenopausal Women: The Women's Health Initiative.J Am Heart Assoc. 2022 Mar;11(5):e024270. doi: 10.1161/JAHA.121.024270. Epub 2022 Feb 22. J Am Heart Assoc. 2022. PMID: 35191329 Free PMC article. Clinical Trial.
-
The benefit of omeprazole exposure on all-cause mortality and length of ICU/hospital stay might vary with age in critically ill pediatric patients: A cohort study.Eur J Clin Pharmacol. 2024 Jan;80(1):115-125. doi: 10.1007/s00228-023-03588-z. Epub 2023 Nov 7. Eur J Clin Pharmacol. 2024. PMID: 37932381
-
Monoaminergic Receptors as Modulators of the Perivascular Sympathetic and Sensory CGRPergic Outflows.Curr Neuropharmacol. 2020;18(9):790-808. doi: 10.2174/1570159X18666200503223240. Curr Neuropharmacol. 2020. PMID: 32364079 Free PMC article. Review.
-
Antacid Therapy in Coronary Artery Disease and Heart Failure: Proton Pump Inhibitors vs. H2 Receptor Blockers.Cardiovasc Drugs Ther. 2024 Feb;38(1):181-189. doi: 10.1007/s10557-022-07358-4. Epub 2022 Jun 18. Cardiovasc Drugs Ther. 2024. PMID: 35715526 Review.
-
Generation and identification of endothelial-specific Hrh2 knockout mice.Transgenic Res. 2021 Jun;30(3):251-261. doi: 10.1007/s11248-021-00244-z. Epub 2021 Mar 30. Transgenic Res. 2021. PMID: 33786748
References
-
- Norton C, Georgiopoulou VV, Kalogeropoulos AP, et al. Epidemiology and cost of advanced heart failure. Prog Cardiovasc Dis 2011;54:78–85. - PubMed
-
- Maintz L, Schwarzer V, Bieber T, et al. Effects of histamine and diamine oxidase activities on pregnancy: a critical review. Hum Reprod Update 2008;14:485–95. - PubMed
-
- Patella V, Marinò I, Arbustini E, et al. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation 1998;97:971–8. - PubMed
-
- Shiota N, Rysä J, Kovanen PT, et al. A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens 2003;21:1935–44. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous